A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers

The American Journal of Medicine
P G O'ConnorS S O'Malley

Abstract

To describe a preliminary investigation of a model of naltrexone therapy and counselling for use by primary care providers and evaluate its impact on drinking behaviors in a cohort of alcohol-dependent subjects. The subjects enrolled in this study were 29 alcohol-dependent individuals. They were managed within a primary care treatment model located at a university-affiliated substance research program in New Haven, Connecticut. Subjects were assigned to a primary care provider for treatment of their alcohol dependence and were placed on naltrexone at a dose of 50 mg per day. They were seen for an initial "new patient" visit and 7 "brief" follow-up visits during the 10-week study. The primary outcomes for this study were completion of treatment, change in drinking behaviors from baseline, change in liver enzymes from baseline, provider ratings of improvement, and patient ratings of improvement and satisfaction with treatment. Of the 29 subjects: 21 (72%) completed treatment, and 10 (35%) relapsed to heavy drinking. All drinking behaviors improved significantly from baseline: percent of days abstinent increased from 36.6% to 88.8% (P < 0.0001), percent days abstinent from heavy drinking increased from 48.7% to 97.3% (P < 0.0001),...Continue Reading

References

Nov 1, 1977·Journal of Studies on Alcohol·R Hingson, N Day
May 1, 1977·Journal of Studies on Alcohol·G EdwardsC Taylor
Nov 15, 1991·Annals of Internal Medicine·D G BuchsbaumM J Lawton
Feb 1, 1988·British Journal of Addiction·J ChickJ Chick
Nov 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·P FaschingW Waldhäusl
Aug 1, 1994·Journal of the American Geriatrics Society·C M CallahanW M Tierney
Aug 17, 1994·JAMA : the Journal of the American Medical Association·R SaitzD R Calkins
Apr 1, 1994·Alcoholism, Clinical and Experimental Research·W R YatesK Brown
Mar 1, 1994·Archives of General Psychiatry·K M CarrollF H Gawin
Mar 1, 1996·Archives of General Psychiatry·S S O'MalleyB Rounsaville
Jan 1, 1996·Journal of Addictive Diseases·D C Lewis
Apr 2, 1997·JAMA : the Journal of the American Medical Association·M F FlemingR London
Aug 14, 2013·The International Journal on Drug Policy·Bach Xuan Tran, Long Thanh Nguyen

❮ Previous
Next ❯

Citations

Sep 1, 2002·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Michael F Fleming
Sep 1, 2002·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·David A FiellinPatrick G O'Connor
Jan 8, 1999·Peptides·G A OlsonA J Kastin
Oct 25, 2000·Alcoholism, Clinical and Experimental Research·D J RohsenowC A Eaton
Mar 21, 2000·The American Journal of Medicine·D A FiellinP G O'Connor
Feb 20, 2004·The American Journal on Addictions·Mary E McCaul, Nancy M Petry
Sep 1, 2000·Journal of the American Geriatrics Society·M Fingerhood
Aug 24, 2000·Seminars in Neonatology : SN·J H Hannigan, D R Armant
Jun 23, 2009·Expert Opinion on Pharmacotherapy·Angela L StottsThomas R Kosten
Jun 1, 2008·Journal of Addiction Medicine·Richard SaitzJeffrey H Samet
Apr 23, 1999·Hospital Practice·S D Kick

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.